US court narrows rules for judging patent disputes:
This article was originally published in Clinica
Executive Summary
In a ruling that impinges on the medical device industry, the US Federal Appeals Court has said that state adjudication in intellectual property matters cannot rely on common law standards such as fraud, but can only be judged by US patent law. The US Court of Appeals for the Federal Circuit reversed a $45 million decision against American Cyanamid last week which was based on claims of fraudulent non-disclosure and unjust enrichment alleged by two doctors from the University of Colorado.